The anti-BAFF antibody belimumab was shown to be efficacious in the treatment of SLE in a phase-3 randomized controlled trial and it was approved by the FDA for the treatment of SLE (209). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.